- Conditions
- Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- IgPro10
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Iowa City, Iowa + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hematologic Malignancies
- Interventions
- Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
- Biological · Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- Duarte, California • Miami, Florida • Tampa, Florida + 4 more
- Conditions
- Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
- Interventions
- Immune Globulin Intravenous (Human), 10%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 24 Months and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
- Drug · Procedure · Biological
- Lead sponsor
- North American Consortium for Histiocytosis
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Immunoproliferative Disorder
- Interventions
- Bacteriophage, rhuCD40L, KLH
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
- Interventions
- Human rabies immune globulin 300 IU/mL
- Biological
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 35 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Anemia, Aplastic, Anemia, Hypoplastic
- Interventions
- h-ATG (ATGAM ), Cyclosporine (Gengraf )
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 82 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Varicella
- Interventions
- TNM005, Placebo, VariZIG
- Drug
- Lead sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- HIV Infections
- Interventions
- Globulin, Immune, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 48
- States / cities
- Downey, California • Long Beach, California • Los Angeles, California + 29 more
- Conditions
- Immunologic Deficiency Syndrome
- Interventions
- Immune Globulin Intravenous (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 6
- States / cities
- Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more
- Conditions
- Spinocerebellar Degenerations
- Interventions
- high-dose intravenous immunoglobulin (IVIG)
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dysmotility Syndrome, Autoimmunity
- Interventions
- Current Intravenous Immunoglobulin (IVIG) treatment, No Intravenous Immunoglobulin (IVIG) treatment
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
- Interventions
- Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more
- Conditions
- Rabies
- Interventions
- SYN023, HRIG (HyperRab), Rabies vaccine
- Biological
- Lead sponsor
- Synermore Biologics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
- Conditions
- Primary Immune Deficiency
- Interventions
- Human Normal Immunoglobulin for Subcutaneous Administration
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Globulin, Immune, Ganciclovir
- Drug
- Lead sponsor
- American National Red Cross
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Pemphigus Vulgaris
- Interventions
- DSG3-CAART, CABA-201
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 13
- States / cities
- Redwood City, California • Sacramento, California • New Haven, Connecticut + 9 more
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
- Interventions
- IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Transplant Rejection
- Interventions
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Cypress, California • Irvine, California • Los Angeles, California + 8 more